Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2151
Ryan Specialty Holdings
RYAN
$11B
| $5.38M | ﹤0.01% |
104,138
-31,307
| -23% | -$1.72M |
|
2152
BOK Financial
BOKF
$8.85B
| $5.37M | ﹤0.01% |
45,367
+42,579
| +1,527% | +$4.77M |
|
2153
Constellium
CSTM
$3.95B
| $5.37M | ﹤0.01% |
285,046
+9,780
| +4% | +$162K |
|
2154
CALL
General Motors
GM
$75.8B
| $5.36M | ﹤0.01% |
65,900
-186,900
| -74% | -$13.2M |
|
|
SNDK
2155
PUT
Sandisk
SNDK
$223B
| $5.36M | ﹤0.01% |
22,572
| – | – |
|
2156
PUT
Under Armour
UAA
$2.3B
| $5.34M | ﹤0.01% |
1,075,000
+850,000
| +378% | +$3.93M |
|
2157
Otter Tail
OTTR
$3.87B
| $5.33M | ﹤0.01% |
65,900
+2,659
| +4% | +$215K |
|
2158
GameStop
GME
$8.33B
| $5.32M | ﹤0.01% |
264,754
-108,346
| -29% | -$2.43M |
|
2159
Provident Financial Services
PFS
$3.24B
| $5.31M | ﹤0.01% |
269,079
+45,552
| +20% | +$881K |
|
2160
California Water Service
CWT
$3.09B
| $5.31M | ﹤0.01% |
122,521
+12,636
| +11% | +$576K |
|
2161
Dorman Products
DORM
$3.97B
| $5.31M | ﹤0.01% |
43,064
+3,504
| +9% | +$473K |
|
|
OSG
2162
Octave Specialty Group
OSG
$210M
| $5.29M | ﹤0.01% |
680,441
+10,928
| +2% | +$93.4K |
|
2163
Immunome
IMNM
$3.18B
| $5.29M | ﹤0.01% |
246,065
+37,552
| +18% | +$659K |
|
2164
AMC Global Media
AMCX
$485M
| $5.26M | ﹤0.01% |
552,709
+2,404
| +0.4% | +$20.3K |
|
2165
FB Financial Corp
FBK
$3.1B
| $5.26M | ﹤0.01% |
94,255
+22,931
| +32% | +$1.28M |
|
|
ORKA
2166
Oruka Therapeutics
ORKA
$7.11B
| $5.25M | ﹤0.01% |
173,329
+77,999
| +82% | +$2.17M |
|
2167
Gates Industrial Corporation Ltd.
GTES
$7.05B
| $5.25M | ﹤0.01% |
244,552
-55,001
| -18% | -$1.27M |
|
|
MH
2168
McGraw Hill
MH
$2.22B
| $5.24M | ﹤0.01% |
317,545
+256,592
| +421% | +$3.72M |
|
2169
Myers Industries
MYE
$1.23B
| $5.24M | ﹤0.01% |
279,858
-23,292
| -8% | -$413K |
|
2170
Healthcare Realty
HR
$6.58B
| $5.24M | ﹤0.01% |
308,948
-443,479
| -59% | -$7.89M |
|
2171
CALL
Samsara
IOT
$24B
| $5.24M | ﹤0.01% |
147,700
-26,300
| -15% | -$1.02M |
|
2172
Kodiak Gas Services
KGS
$6.26B
| $5.22M | ﹤0.01% |
139,682
+23,330
| +20% | +$825K |
|
2173
Seacoast Banking Corp of Florida
SBCF
$3.44B
| $5.22M | ﹤0.01% |
166,050
+39,356
| +31% | +$1.23M |
|
2174
Huron Consulting
HURN
$2.39B
| $5.21M | ﹤0.01% |
30,142
+4,369
| +17% | +$715K |
|
2175
Calix
CALX
$2.51B
| $5.2M | ﹤0.01% |
98,322
+9,055
| +10% | +$527K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.